China-Japan Union Hospital of Jilin University, Changchun, China.
The Third Norman Bethune Clinical College of Jilin University, Changchun, China.
Front Endocrinol (Lausanne). 2022 Jul 28;13:927324. doi: 10.3389/fendo.2022.927324. eCollection 2022.
Diabetes is a complex metabolic disorder of carbohydrate metabolism, characterized by high blood glucose levels either due to an absolute deficiency of insulin secretion or an ineffective response of cells to insulin, a hormone synthetized by β-cells in the pancreas. Despite the current substantial progress of new drugs and strategies to prevent and treat diabetes, we do not understand precisely the exact cause of the failure and impairment of β-cells. Therefore, there is an urgent need to find new methods to restore β-cells. In recent years, pluripotent stem cells (PSCs) such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC) can serve as an ideal alternative source for the pancreatic β-cells. In this review, we systematically summarize the current progress and protocols of generating pancreatic β-cells from human PSCs. Meanwhile, we also discuss some challenges and future perspectives of human PSCs treatments for diabetes.
糖尿病是一种复杂的碳水化合物代谢紊乱,其特征是血糖水平升高,要么是由于胰岛素分泌绝对不足,要么是由于细胞对胰岛素(一种由胰腺β细胞合成的激素)的反应无效。尽管目前在预防和治疗糖尿病方面有新的药物和策略取得了实质性进展,但我们并不确切了解β细胞功能障碍的确切原因。因此,迫切需要寻找新的方法来恢复β细胞。近年来,多能干细胞(PSCs),如胚胎干细胞(ESCs)和诱导多能干细胞(iPSC),可以作为胰腺β细胞的理想替代来源。在这篇综述中,我们系统地总结了从人 PSCs 中生成胰腺β细胞的最新进展和方案。同时,我们还讨论了人 PSCs 治疗糖尿病的一些挑战和未来展望。